Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | MAP2 | P11137 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562237 | 0.88 | KDM4E (0.53) | MAPTKDM4EALDH1A1GAALMNA | |
| SCHEMBL15711419 | 0.83 | MAP2 (0.64) | MAPTKDM4EALDH1A1LMNATHRB | |
| SCHEMBL21801485 | 0.83 | CNR1 (0.68) | KDM4EALDH1A1SIRT1CNR1 | |
| SCHEMBL17221790 | 0.83 | MAPT (0.59) | MAPTKDM4EALDH1A1GAALMNA | |
| SCHEMBL3037898 | 0.83 | MAP2 (0.63) | MAPTALDH1A1GAALMNATHRB | |
| SCHEMBL29223458 | 0.81 | LMNA (0.56) | MAPTKDM4EALDH1A1GAALMNA | |
| SCHEMBL8689806 | 0.81 | MAP2 (0.62) | MAPTKDM4EALDH1A1GAALMNA | |
| SCHEMBL4406172 | 0.79 | MAPT (0.55) | MAPTKDM4EALDH1A1CNR1 | |
| SCHEMBL6846691 | 0.79 | CNR1 (0.53) | MAPTKDM4EALDH1A1LMNATHRB | |
| SCHEMBL7675702 | 0.78 | GAA (0.63) | MAPTKDM4EALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-08-18 | — | — | US | disclosed |
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-08-18 | — | — | US | disclosed |
| WO-2020051707-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2020-03-19 | — | — | WO | disclosed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | MAPT 4140/4885KDM4E 2887/4885ALDH1A1 144/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | MAPT 4140/4885KDM4E 2887/4885ALDH1A1 144/4885 |
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | CNR2, GPR119, CNR1 | MAPT 2269/4885KDM4E 3057/4885ALDH1A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.